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We review insights from computational studies of affinities of ligands binding to proteins. The power of
structural biology is in translating knowledge of protein structures into insights about their forces, binding,
and mechanisms. However, the complementary power of computer modeling is in showing ‘‘the rest of the
story’’ (i.e., how motions and ensembles and alternative conformers and the entropies and forces that
cannot be seen in single molecular structures also contribute to binding affinities). Upon binding to a protein,
a ligand can bind in multiple orientations; the protein or ligand can be deformed by the binding event;
waters, ions, or cofactors can have unexpected involvement; and conformational or solvation entropies
can sometimes play large and otherwise unpredictable roles. Computer modeling is helping to elucidate
these factors.Introduction: Computer Modeling Is an Important Tool
for Understanding Ligand Binding to Proteins
Structure-based computer modeling of ligand-protein interac-
tions is now a core component of modern drug discovery
(Charifson and Kuntz, 1997). It is now difficult to imagine the
drug discovery process without computation (Jorgensen,
2004). Computational methods have played a key role in the
drug discovery process for a growing number of marketed
drugs, including HIV protease inhibitors (Charifson and Kuntz,
1997; Greer et al., 1994; Jorgensen, 2004) and zanamivir (an
antiviral neuraminidase inhibitor) (von Itzstein et al., 1993), and
in the development of new drug candidates, such as HIV
integrase inhibitors (Hazuda et al., 2004; Schames et al., 2004),
hepatitis C protease inhibitors (Liverton et al., 2008; Thomson
and Perni, 2006), and beta-secretase inhibitors (BACE-1)
(Stauffer et al., 2007).
An early step in this field was the invention of the DOCK
method in 1982 (Kuntz et al., 1982). There are now at least four
classes of physical computer methods (listed from fastest to
slowest, and least physical to most physical): (1) very fast molec-
ular docking methods, including DOCK, Glide, AutoDock, FlexX,
ICN, PMF, and GOLD, (2) approximate free energy methods, in
which the solvent and protein motions are taken into account
with fewer approximations, (3) relative binding free energy
(RBFE) methods, which include full solvent and protein motions,
but which require prior knowledge of the structure of a complex
of the protein with a ligand that is similar to the one of interest,
and (4) absolute binding free energy (ABFE) methods, which
are the most expensive computationally, but which include the
physics in the most rigorous way that is currently practical (see
Figure 1). ABFE methods start from an unbound ligand and
potentially the unbound structure of the protein to attempt to
predict the structures, affinities, and thermal properties of the
complexes of interest. Mining minima is another method that is
very nearly in this last category and has provided insight into
binding (Chang and Gilson, 2004; Gilson and Zhou, 2007;
Head et al., 1997).StDifferent Computer Methods Trade Off Speed versus
Physical Accuracy
First, we define some terms. A lead compound is a molecule,
typically in early-stage drug discovery, that can be further chem-
icallymodified to improve its properties as a possible drug candi-
date. A complex is a receptor and ligand bound together. A pose
is one conformation of a ligand in a complex and specifies both
the ligand conformation and its position relative to the receptor.
A pose can refer either to a conformation that is known from an
experimental structure of a complex, or to a hypothetical confor-
mation generated in a computer model. The apo form refers to
the structure of the protein that has no ligand bound to it. The
holo form refers to the structure of the protein when it is
complexed with ligand. The binding free energy, DGo, is the
free energy of the complex minus the free energies of the ligand
and apo protein separately in aqueous solution. The binding free
energy is related to the equilibrium association constant, Ka, (in
units of M1) by DGo = RT ln (Co Ka), where R is the gas
constant, T is the absolute temperature, and Co is the standard
concentration (1 M). The binding affinity, or dissociation
constant, equals 1/Ka. The binding free has two components,
DG = DH – TDS, where H is the enthalpy and S is the entropy.
Here are some of the key approaches used for studying binding.
Docking
Docking methods start with a known protein structure and
a known ligand structure and aim to rapidly generate an optimal
protein-ligand bound conformation. Docking was designed to be
very rapid (seconds or less per compound), which is desirable for
screening large libraries in the short times required for modern
pharmaceutical lead discovery. Docking explores many ligand
conformations and orientations, and in some cases even
different potential binding sites. The different poses are rank
ordered by a score, a quantity that ideally would correlate with
the free energy of binding, and is obtained either from a physical
or knowledge-based potential. Often, docking approaches treat
the protein as completely rigid, having a single fixed receptor
conformation. Other docking methods treat protein motions byructure 17, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 489
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docking approaches can allow for some motions of side chains
or backbone (Corbeil et al., 2007; Cozzini et al., 2008; Leach,
1994; Meiler and Baker, 2006; Sherman et al., 2006; Wei et al.,
2004), treating these degrees of freedom slows down the
computations considerably. Docking is an appealing way to
generate leads (Shoichet et al., 2002) because of its speed and
ability to screen large libraries of potential leads (Huang and
Jacobson, 2007; Babaoglu et al., 2008). But because docking
trades off physical accuracy for speed, it is seldom accurate
enough to predict binding affinities or rank-order compounds.
Its power to discriminate binders from nonbinders varies widely
depending on the target protein (Graves et al., 2008; Warren
et al., 2006). But because of its speed, docking approaches
are the method of choice for filtering out compounds that are
likely nonbinders and for identifying native-like poses.
MM-PBSA/GBSA
MM-PBSA/GBSA is more physically rigorous than docking.
The acronym stands for molecular mechanics with Poisson-
Boltzmann + surface area or MM-GBSA (GB stands for General-
ized Born), and the method was originated by the Kollman and
Case labs in the late 1990s (Cheatham et al., 1998; Kollman
et al., 2000; Srinivasan et al., 1998), with parallel work by others
(Vorobjev and Hermans, 1999). It involves greater computational
cost than docking (at least several hours per compound), but
also is more physical in its more extensive conformational
sampling. MM-PBSA aims to estimate the binding free energies,
or relative binding free energies, of related compounds. Here,
a computer generates representative bound and unbound
structures by molecular mechanics simulations or by energy
minimization of a protein-ligand complex, usually in explicit
solvent. The goal is to estimate the change in enthalpy on binding
by comparing the average enthalpy of bound and unbound
states, but this would be a small difference of two large, noisy
energies. So after the all-atom simulations, the water is removed
and the enthalpies and binding free energies are estimated using
an implicit (Poisson-Boltzmann or Generalized Born) representa-
tion of water. The binding free energy estimate includes the
Figure 1. Relative Publication Numbers
for Different Computational Methods
From Google Scholar (July 2008). MM-PBS,
molecular-mechanics with Poisson-Boltzmann
surface area; RBFE, relative binding free energy;
ABFE, absolute binding free energy. Percentages,
in the order listed in the legend, are 88%, 1%,
11%, and 0.04%.
enthalpy change plus the change in
salvation free energy from the implicit
solvent model.
In many cases, an approximate value
of the entropy is also estimated from
these simulations. Because MM-PBSA/
GBSA invests more effort in sampling
and entropies, it is closer to a true free
energy calculation. However, often,
because of limitations in the approxima-
tions for estimating entropy (Gilson and
Zhou, 2007), entropic contributions are omitted when estimating
relative binding strengths, in the hope that these contributions
will cancel when comparing similar ligands (Gilson and Zhou,
2007; Shirts et al., 2009).
Early results with the MM-PBSA method were quite promising
(typically with mean-squared errors under 3 kcal/mol for the first
several years) (Huo et al., 2002; Kuhn and Kollman, 2000; Mardis
et al., 2001; Rizzo et al., 2004; Schwarzl et al., 2002; Shirts et al.,
2009), but more recent studies have seen larger errors in some
cases (Shirts et al., 2009). Applications have typically been
limited to single targets, so it is difficult to evaluate how well
the method does generally.
The drawbacks of MM-PBSA/GBSA are that it, too, is
sometimes not predictive (Pearlman, 2005; Shirts et al., 2009;
Steinbrecher et al., 2006) and it requires prior knowledge of
a likely bound complex as a starting point, although such starting
conformations can be taken from prior docking (Steinbrecher
et al., 2006).
Relative Binding Free Energies
A still more rigorous approach uses the energetics of a physical
force field and extensive conformational sampling from molec-
ular dynamics simulations to actually compute differences in
binding free energies between similar ligands. This can be
done using computational alchemy to obtain the difference in
binding free energies, DDGA/B. This is the free energy of
changing ligand A into ligand B in the receptor, minus the free
energy of changing A into B in solution. To compute this free
energy difference for just one pair of ligands binding to the
same protein can cost several hundred CPU days. These relative
free energies can be computed precisely—given sufficiently long
molecular dynamics simulations—using one of several different
analysis techniques (Shirts et al., 2007). Though the accuracy
of the binding free energies obtained from this method depends
on the accuracy of the underlying molecular mechanics force
field, it does treat fully, at least in principle, free energies associ-
ated with conformational change as well as entropies.
The first alchemical calculations were performed in the 1980s
in the McCammon lab (Tembe and McCammon, 1984; Wong490 Structure 17, April 15, 2009 ª2009 Elsevier Ltd All rights reserved
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Subramaniam, 1986; Warshel et al., 1986; Bash et al., 1987;
Shirts et al., 2007). Limitations of these methods are the high
computational costs and the need to know at least one bound
structure of a similar ligand in the protein as a starting point.
Accuracies are generally better than for MM-PBSA (Pearlman,
2005; Steinbrecher et al., 2006) and docking (Mobley et al.,
2007b; Pearlman and Charifson, 2001), but few systematic
comparisons have been done. These methods are only useful
for comparing related ligands or receptors.
Absolute Binding Free Energies
The most powerful approach, in principle, is the method of
absolute binding free energies (ABFE) (Boresch et al., 2003;
Hermans and Wang, 1997; Roux et al., 1996). Like RBFE
methods, ABFEmethods also use full molecular dynamics simu-
lations with fully detailed atomic force fields, and also involve
separate sets of simulations for the solvated ligand, the solvated
protein, and the complex. But ABFEmethods do not require prior
knowledge of the binding affinity of a related ligand, hence the
term absolute. There havebeen twogroupsof ABFEapproaches.
The first begins with the structure of the ligand of interest bound
to the protein. However, the ultimate goal is to begin with no prior
knowledge of either the structure or affinity of the ligand complex.
A second, more recent group replaces starting knowledge of the
structure with one or more docking poses (Mobley et al., 2006,
2007b; Jayachandran et al., 2006). Various studies suggest that
ABFE methods are fairly accurate, with good correlations to
experimental binding affinities and with RMS errors often less
than 3 kcal/mol (Deng and Roux, 2006; Fujitani et al., 2005;
Jayachandran et al., 2006; Mobley et al., 2007b; Shirts et al.,
2007; Wang et al., 2006), and sometimes much better.
Ligand Binding Is Described by Energy Landscapes,
Not Just Single Structures
The enterprise of structural biology has given us powerful ‘‘eyes’’
to see single structures—specific native structures and specific
bound complexes—and some of the driving forces that hold
them together: hydrogen bonds, hydrophobic interactions, ion
pairing, and van der Waals packing. However, ‘‘what you see’’
is not always ‘‘what you get.’’ Other equally important forces,
namely the entropies, are not visible in native structures.
To capture both the observable and nonobservable contribu-
tions to the energetics, it is important to note that binding takes
place on an energy landscape. Exploring energy landscapes
often requires modeling and computer simulations. For binding,
the energy landscape is the free energy of the system as a func-
tion of its degrees of freedom, which are many, and include
translational, rotational, conformational, and solvation degrees
of freedom.
Upon Binding, a Ligand Loses Translational
and Rotational Entropy
Relative to a receptor, a ligand has three translational degrees of
freedom (x, y, and z directions) and three orientational degrees of
freedom. When bound, motion in these degrees of freedom
becomes restricted. This loss of freedom results in an entropic
and free energy cost, opposing binding and favoring the dissoci-
ated state (Chang et al., 2007; Chang and Gilson, 2004; Chen
et al., 2004; Deng and Roux, 2006; Lee and Olson, 2006; Wang
et al., 2006). The loss of freedom depends on the mobilityStrremaining in the binding site, so that in a series of increasingly
tightly bound structures there will be increasing losses in trans-
lational and rotational entropies, resulting in a contribution
opposing binding.
Upon Binding, a Ligand Can Lose Internal Freedom
and Entropy
Some simple models assume that the ligand entropy lost on
binding correlates with the number of rotatable bonds in the
ligand (Bo¨hm, 1993; Gilson and Zhou, 2007; Huey et al., 2007;
Laederach and Reilly, 2003; Taylor et al., 2002; Gohlke and
Klebe, 2002). The ligand is envisioned to start in its unbound
state having access to all possible conformers and to end in its
bound state having a single conformer. However, interestingly,
more rigorous recent computational studies in host-guest
systems indicate that losses in ligand conformational entropy
on binding are not strongly correlated with the number of rotat-
able bonds (Chang and Gilson, 2004; Chen et al., 2004; Guimar-
aes and Cardozo, 2008). Recent work on salvation free energies
of small molecules has led to similar conclusions (Mobley et al.,
2008). Not all small-molecule conformers are populated equally
in solution. Thus computing accurate ligand affinities (and
entropy losses) requires more accurate treatments of the
different ligand populations in solution. Entropic contributions
can also vary between different conformations of the same
ligand in a particular receptor (Chen et al., 2004; Gilson and
Zhou, 2007), whichmay be important even for docking (Ruvinsky
and Kozintsev, 2005).
A Ligand Can Bind to a Receptor in Different Poses
A ligand can sometimes adopt multiple different conformations
or orientations upon binding (see Figure 2). These different poses
can be separated by energetic barriers. In some cases the
different poses are due to ligand or protein symmetries. HIV-1
protease is a dimer with a nearly symmetric active site; as
a result, many HIV protease inhibitors have two nearly identically
Figure 2. Hypothetical Ligand Binding Energy Landscape
Ligand binding energy landscapes (top) can be rough, with multiple minima.
These multiple minima can correspond to multiple distinct ligand binding
conformations in the receptor (bottom).ucture 17, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 491
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Modify the Binding Landscape
It is not uncommon to find that small modifications
in a ligand (bottom) may lead to drastic changes in
the observed binding mode (bottom) (Stout et al.,
1999; Badger et al., 1988; Bo¨hm and Klebe,
1996; Kim, 2007a, 2007b; Pei et al., 2006; Reich
et al., 1995; Stoll et al., 2003). This can be
explained by an energy landscape with multiple
minima (top), which is altered slightly by minor
modifications to the ligand (top left versus top
right), leading to a substantial change in the
binding mode.binding modes (e.g., see Protein Data Bank [PDB] codes 1AXA,
1IZH, 1MUI, and 1U8G). Ligand symmetries can lead to trivial
cases of multiple binding modes, which have significant entropic
implications. Multiple binding modes are observed also when
symmetries do not play a role. Computational studies show
multiple distinct ligand binding modes in binding sites in T4
lysozyme (Mobley et al., 2006, 2007b), neutrophil elastase
(Steinbrecher et al., 2006), estrogen receptor inhibitors (Oosten-
brink and van Gunsteren, 2004), FKBP inhibitors (Jayachandran
et al., 2006), biotin and streptavidin (Lazaridis et al., 2002), and
cytochrome P450cam (Paulsen and Ornstein, 1992).
Do experimental studies support these predictions of multiple
ligand conformations? The challenge is that multiple conformers
are difficult to determine experimentally. But there is at least
some direct crystallographic evidence suggesting multiple
relevant orientations: in T4 lysozyme (Graves et al., 2005; Mobley
et al., 2006, 2007b), influenza neuraminidase (Stoll et al., 2003)
and possibly in trypsin (Stubbs et al., 2002), where the binding
mode is affected by pH. Multiple binding modes of fragment-
like kinase inhibitors have also been observed (Constantine
et al., 2008). Multiple orientations or binding modes have also
been seen in thymidylate synthase (Montfort et al., 1990), in
the binding of an HIV-1 cell entry inhibitor to the core of HIV-1
gp41 (Zhou et al., 2000), the binding of a transition state analog
to an AmpC beta lactamase mutant (Chen et al., 2006), the
binding of thiocamphor to cytochrome P450cam (Raag and
Poulos, 1991), the binding of flavin to para hydroxybenzoate
hydrolase (Gatti et al., 1994), and in the binding of some HIV-1
protease inhibitors (Murthy et al., 1992). There is additional
evidence for multiple orientations in several other cases (Birdsall
et al., 1989; Bo¨hm and Klebe, 1996; Lazaridis et al., 2002;
Mewshaw et al., 2005; Orville et al., 1997; Uytterhoeven et al.,
2002). Spectroscopic data (Deng et al., 2001) and studies of
drastically different binding modes of related inhibitors (Figure 3)
(Stout et al., 1999; Badger et al., 1988; Bo¨hm and Klebe, 1996;
Kim, 2007a, 2007b; Pei et al., 2006; Reich et al., 1995; Stoll
et al., 2003), some of which may have multiple binding modes
(Montfort et al., 1990), suggest that multiple binding modes
may be relatively common.
Proteins Wiggle, and May Have Multiple Conformers
in Both the Bound and Unbound States
It is not only ligands that can have multiple binding modes.
Proteins can, too (Mobley et al., 2007a, 2007b). We refer here
not to induced fit, where the ligand binding event causes492 Structure 17, April 15, 2009 ª2009 Elsevier Ltd All rights reservea change in protein conformation. Rather, we focus on internal
motions or freedom of the protein that occur either in the apo
structure of the protein itself or in the complex itself. Compari-
sons of different apo structures of the same proteins show that
there are some rotamer changes near binding sites even in the
absence of the ligand (Najmanovich et al., 2000), suggesting
that multiple rotameric states may be relevant; this is also
supported by NMR data (Chou and Bax, 2001). Structural data
in the apolar T4 lysozyme binding cavity suggests that helix F,
which borders on the binding cavity, can undergo substantial
motions of 1.5–2.5 A˚ with little free energy cost (Morton and
Matthews, 1995); various other motions occur in T4 lysozyme
as well (Zhang et al., 1995). DHFR appears to have multiple
relevant conformations, both in isolation and when binding
ligands, and the populations are modulated by pH (Birdsall
et al., 1989); each state in the catalytic cycle appears to have
at least partially occupied conformations that resemble those
before or after it in the cycle (Boehr et al., 2006). Crystallographic
evidence suggests multiple protein conformations due to
domain motion in some cases (Ma et al., 2002). Multiple
conformers are also seen in host-guest binding (Chang and
Gilson, 2004; Chen et al., 2004) and can be critical for protein
mechanisms such as enzyme catalytic motions (Eisenmesser
et al., 2005; Arora and Brooks, 2007; Henzler-Wildman et al.,
2007; Henzler-Wildman and Kern, 2007). Several other studies
also have provided evidence for multiple protein conformations
(Eisenmesser et al., 2002; Gerstein et al., 1994; Min et al.,
2005a, 2005b; Fragai et al., 2006).
Strain: A Measure of the Free Energy of Deformation
Ligand binding to a protein may induce strain. Strain refers to an
energy cost, usually associated with a deformation of some sort.
To achieve the lowest free energy of binding in the complex, the
protein and/or ligand may become deformed relative to its
unbound state in solvent, which costs energy (strain). Computa-
tional studies in the apolar lysozyme model binding site have
found that protein strain energies for a valine side-chain rotamer
change can be 3–4 kcal/mol (Deng and Roux, 2006; Mobley
et al., 2007a, 2007b). When such strain energies are not taken
into account, it leads to errors in predicted binding free energies
(Mobley et al., 2007a, 2007b).
Computational modeling suggests that ligand strain free ener-
gies can be significant. In a survey of 150 crystallographic
protein-ligand complexes, Perola and Charifson (2004) used
molecular mechanics scoring functions to assess strain energiesd
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had strain energies more than 3 kcal/mol, and, overall, 40% of
ligands had strain energies more than 5 kcal/mol. Another study
computed quantum mechanical torsional potentials for a variety
of PDB ligands and found that typical strain energies could be on
the order of 0.6 kcal/mol per torsion motif, amounting to roughly
3 kcal/mol for a ligand with five torsion motifs (Hao et al., 2007).
Another study found, for several ligands, that free energy costs of
restricting the ligand to the bound conformation could be a few
kcal/mol (Tirado-Rives and Jorgensen, 2006). More recent
work suggests that these values could be overestimates of
the true strain, as crystal structures (from which strain is esti-
mated) may be refined with a different force field than is used
in estimating the strain, introducing artifacts. Nevertheless,
strain energies often appear to be greater than several kT (Huang
et al., 2006). See also Warren and Perola’s (Warren and Perola,
2008) presentation on the topic from OpenEye’s CUP meeting
(http://www.eyesopen.com/about/events/cups-2008/pdfs-CUP/
CUP9-Field-of-Extremes.pdf). Apparently, binding interactions
can be strong enough to pay a substantial strain price for
deforming one or both partners. Hence the true bound structure
of a complex will not be the one that maximizes the interaction
energy between the receptor and ligand, but rather the one
that best balances the tradeoff between gaining additional
favorable interactions while also inducing strain (Sharp, 2005).
Some experiments support this contention that strain free
energies can be substantial. In an NMR study onmaltose binding
protein, Tang et al. (2007) found that the unbound protein was
predominantly (roughly 95%) in the open apo conformation,
and had a smaller (roughly 5%) population in aminor apo confor-
mation that was more like the holo conformation, but with no
evidence that it populated the holo conformation at all in the
absence of the ligand. Thus the minor apo conformation is
roughly 1.7 kcal/mol less favorable than the major apo confor-
mation, and the holo conformation is probably still more unfavor-
able. In another instance, in NtrCr, a conformational switch in
bacteria that undergoes a conformational change upon phos-
phorylation, the active conformation has been shown to be
partially populated even when the protein is unphosphorylated
(Volkman et al., 2001), but with a smaller population. Based on
the populations, this active-like conformation is about 2 kcal/
mol less favorable than the norm in active conformation. So,
functional protein conformational changes can make significant
contributions to the thermodynamics.
Ligand Binding Can Cause Conformational Change
in Protein Structures
When a ligand binds to a protein, it causes conformational
changes in the protein. This may or may not be accompanied
by strain in the protein, as strain is an (invisible) energy cost.
Ligand-induced protein conformational changes are not rare
events. Comparisons of apo and holo structures from the PDB
show that backbone conformational motions on ligand binding
are relatively common; 20% of binding residues (Gutteridge
and Thornton, 2005) and 25% of binding sites (Najmanovich
et al., 2000) across a variety of proteins have backbone Ca
motions more than 1 A˚. And 15% of binding site residues have
side-chain motions of more than 2 A˚ (Gutteridge and Thornton,
2005), whereas only 30%–40% of binding sites have been
shown to undergo no side-chain rotamer changes (NajmanovichStet al., 2000). More anecdotal reports of conformational changes
on ligand binding are available for a wide range of systems;
kinases, for example, are notoriously flexible (Noble et al.,
2004; Vajpai et al., 2008; Weisberg et al., 2007), as are many
other proteins (Bo¨hm and Klebe, 1996; Kim, 2007a; Meiler and
Baker, 2006; Teague, 2003). An extreme example may be
natively disordered proteins in which large parts of the protein
may become ordered upon interacting with binding partners
(Hilser and Thompson, 2007; Radivojac et al., 2007; Wright and
Dyson, 1999).
In addition, a given protein can adopt different conformations
for different ligands. A PDB study of 206 binding site pairs (each
pair consisting of two structures of the same protein with
different, similar ligands in the binding site) showed that in
83% of the cases there were significant conformational changes
in the binding sites between pair members (Bostrom et al., 2006);
changes were judged significant if the RMSD for all side-chain
atoms if at least one amino acid residue within 5 A˚ of the ligand
is greater than 1.0 A˚. The most frequent differences were
changes in water architecture and side-chain conformation
(both occurring in over 50% of the pairs). Significant backbone
conformational changes occurred in only 7% of the set; changes
were judged significant if the RMSD of at least one backbone
heavy atom in three or more consecutive amino acids is more
than 0.5 A˚. A smaller study found examples of substantial confor-
mational changes on binding similar ligands for a variety of
systems as well (Kim, 2007a). It is even possible for a single
ligand to bind to different protein conformations under different
solution conditions (Miller and Dill, 1997). Thus, changes in
binding site architecture, at least at the side-chain and water
level, should be regarded as the rule, rather than the exception.
Small Changes in Conformation Can Cause Big Changes
in Binding Affinities
Some computational studies predict that even when a binding
site structure is not perturbed very much, its energetics can
change substantially. For example, simulations show that
neglecting even small protein motions can lead to large errors
(RMS errors relative to experiment of nearly 20 kcal/mol when
protein motions are not allowed), relative to much smaller errors
(1.7 kcal/mol RMS) when protein motion is allowed. Even small
relaxations of the protein reduced the RMS errors to 4–5 kcal/
mol) (Mobley et al., 2007b). This is important for both conceptual
and practical reasons. Conceptually, it means the strength or
quality of binding interactions is sensitive to minute details of
the bound structure and is not easily assessed by simple metrics
like hydrogen bond counts or apparent fit. Practically, it means
that free energy methods that include these protein conforma-
tional changes can potentially have much higher accuracy than
docking methods that neglect them.
The conclusion that these small changes can make big differ-
ences in the energetics is supported by a variety of docking and
(re)scoring studies that have looked at the effects of introducing
small amounts of protein flexibility. Though scores do not neces-
sarily improve for all ligands, they do typically change substan-
tially, showing some improvement (Graves et al., 2008; Huang
et al., 2006; Meiler and Baker, 2006; Sousa et al., 2006; Wei
et al., 2004). But introducing protein flexibility without accounting
for protein strain energies can potentially increase false positive
rates bymaking binding sites too permissive (Graves et al., 2008;ructure 17, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 493
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of conformational change and strain.
Differences in Solvation Can Contribute
to Binding Affinities
Several detailed binding free energy studies have suggested that
differences in solvation may play an important role in differences
in binding free energy between relatively similar compounds
(Jiao et al., 2008; Reddy and Erion, 2001). Two molecules might
have similar interactions with a protein, similar strain energies,
etc., but have different solvation properties in water, leading
to solvation-driven differences in binding free energies. These
differences may not always be intuitive. For example, the
N-methylacetamide/amine ‘‘problem’’ (Rizzo and Jorgensen,
1999) suggests that adding a hydrophobic methyl group to acet-
amide or ammonia increases the affinity for water, whereas
subsequent methylations decrease the affinity.
The importance of solvation and desolvation is supported by
an emerging trend toward including approximate estimates of
solvation/desolvation energies in approximate docking methods
for scoring protein-ligand binding. Including such estimates
appears to result in improved scoring (Ferrara et al., 2004; Gilson
and Zhou, 2007;Shoichet et al., 1999). Without these contribu-
tions, charged ligands can wrongly appear to bind better than
polar ligands in a polar binding site. A charged ligand may
make favorable electrostatic interactions in a polar binding
site, but it also costs a huge amount of energy to remove it
from water (Brenk et al., 2006; Gilson and Zhou, 2007; Shoichet
et al., 1999). In other cases, a small modification to a ligand can
potentially lead to affinity gains due to a change in the desolva-
tion cost (Kangas and Tidor, 2001).
Bound Waters Usually Contribute Favorably to Ligand
Binding, But Not Always, and Their Contributions
Are Highly Variable
Computer simulations have been used to study the role of
crystallographic waters in binding thermodynamics (Barillari
et al., 2007; Hamelberg and McCammon, 2004; Lu et al., 2006;
Olano and Rick, 2004; Zhang and Hermans, 1996; see also
Helms andWade [1995, 1998a, 1998b] for desolvation of a buried
binding cavity). In many cases, binding or ordering of waters
occurs concurrently with ligand binding, so it can be extremely
difficult to experimentally assess the contribution of water
binding to overall binding thermodynamics. Computational
methods can directly compute the free energy of inserting or
removing a water molecule from a binding site, providing key
insight that is hard to obtain experimentally.
These computational studies indicate that bound waters
contribute substantially to binding free energies, contributing
as much as 10 kcal/mol for some waters (Barillari et al.,
2007), but smaller values between 3 and 6 kcal/mol are
more typical (Barillari et al., 2007; Hamelberg and McCammon,
2004; Lu et al., 2006; Olano andRick, 2004; Zhang andHermans,
1996). In some cases, crystallographic waters appear substan-
tially unfavorable relative to bulk, raising the possibility of prob-
lems with refinement or force fields (Barillari et al., 2007; Olano
and Rick, 2004). Perhaps ligands can be designedwith improved
affinities by recognizing nearby sites where waters can be easily
displaced (Abel et al., 2008; Pan et al., 2007).
Sometimes ligand binding can involve concerted reordering of
many water molecules. In some hydrophobic sites in proteins494 Structure 17, April 15, 2009 ª2009 Elsevier Ltd All rights reservethat bind fatty acids or lipids, whole networks of more than
a half-dozen water molecules shift their structures to form
a ‘‘hydrophobic’’ interface with the ligand (LaLonde et al.,
1994; Sulsky et al., 2007).
Protonation States Can Change on Binding,
Influencing Affinity
Binding free energies can also be affected by other unseen and
unexpected factors. For example, protonation states can
change on binding (Czodrowski et al., 2007; Dullweber et al.,
2001; Gohlke and Klebe, 2002; Steuber et al., 2007), as can
tautomeric states (Pospisil et al., 2003) and other factors. In
some cases, multiple protonation or tautomeric states can be
relevant, as observed crystallographically for one CDK2 inhibitor
(Furet et al., 2002) and hypothesized in another instance (Lee
et al., 1996). ‘‘Similar’’ ligands may also adopt different proton-
ation states on binding (Dullweber et al., 2001).
Perspective
We have reviewed some recent computational studies of ligand
binding to proteins. Ultimately, to predict accurate binding affin-
ities, it will be necessary to go beyond predicting a single ‘‘domi-
nant’’ conformation of the ligand complexed with the protein.
Binding free energy is not driven by a single conformation, but
rather by the free energy landscape. It is the shape of the energy
landscape that is crucial, the shape and width of the minima
influences entropies. Entropies are key contributors to binding
thermodynamics and are not observable in single bound struc-
tures. Other factors about the full landscape also play key roles,
such as multiple ligand poses, protein conformations, strain
energies, changes in water structure, and solvation and proton-
ation all play roles. And none of these are observable in single
structures. Computational tools can help provide insight into
the unseen landscape, so those doing crystallographic studies
may want to complement their work by using computational
tools to explore this landscape. And those relying on crystallo-
graphic data (e.g., in a drug design context) should be aware
that there are various binding possibilities that might not be
captured in a single crystal structure.
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